Holdings

Rhenman & Partners Asset Management AB

As of Sep 30, 2026, Rhenman & Partners Asset Management AB reported 87 positions worth US$800M. Largest: Iovance Biotherapeutics, Inc., Merck & Company, Inc. and UnitedHealth Group Incorporated. What it bought and sold, with each filing.

CompanySharesValue as reportedChangeAs of
Iovance Biotherapeutics, Inc.2.5MUS$37.1M+797KSep 30, 2026
Merck & Company, Inc.207KUS$30.1M−6,600Sep 30, 2026
UnitedHealth Group Incorporated71,400US$26.2M−22,200Sep 30, 2026
Vertex Pharmaceuticals Incorporated48,935US$25.6M+18,250Sep 30, 2026
Gilead Sciences, Inc.159KUS$23.7M−19,200Sep 30, 2026
Edwards Lifesciences Corporation273KUS$23.6M+13,000Sep 30, 2026
BioMarin Pharmaceutical Inc.387KUS$23.2M+96,400Sep 30, 2026
Biogen Inc.97,050US$21.9M+2,200Sep 30, 2026
Eli Lilly and Company18,875US$21.8M−3,440Sep 30, 2026
Insmed Incorporated187KUS$21.4M+35,120Sep 30, 2026